Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced the election of Mark S. Davis to its Board of Directors, effective immediately, expanding the Board ...
Additional new data will show how Myriad’s second-generation tumor-informed molecular residual disease (MRD) assay demonstrated high sensitivity, specificity and measurement accuracy, which, together, ...